Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.

Targeted oncology - 1 Feb 2020

Voutsadakis Ioannis A

Abstract excerpt

BACKGROUND: The recent development of effective immunotherapies with immune checkpoint inhibitors for the treatment of cancer has rekindled the interest for the immune system and its activation for an anti-cancer response. At the same time, it has become evident that not all types of cancers respond equally to these treatments, and even within the same tumor type only a subset of patients derive clinical benefit....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 31741177
DOI: 10.1007/s11523-019-00689-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.PMID 31741177Read ↗

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.Semantic proximity Read ↗

Prevalence and molecular features of TMB-high and MSI-high breast cancer assessed by gene panel testingSemantic proximity Read ↗

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.Semantic proximity Read ↗

Prevalence and mutational determinants of high tumor mutation burden in breast cancer.Semantic proximity Read ↗

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.Semantic proximity Read ↗

Prevalence and mutational determinants of high tumor mutation burden in breast cancerSemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read ↗

Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breastSemantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

The Predictive Effect of Tumor Mutation Burden on prognosis in Breast cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.